How to buy Kymera Therapeutics stock

Kymera Therapeutics, Inc is a biotechnology business based in the US. Kymera Therapeutics shares (KYMR) are listed on the NASDAQ and all prices are listed in US Dollars. Kymera Therapeutics employs 64 staff and has a trailing 12-month revenue of around USD$23.1 million.

How to buy shares in Kymera Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Kymera Therapeutics. Find the stock by name or ticker symbol: KYMR. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Kymera Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Kymera Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Kymera Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Building a portfolio

Sofi Invest

Our top pick for

Advanced traders

Interactive Brokers

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.
• Our pick for active traders. We picked Interactive Brokers for this category because it offers advanced tools and low fees for active investors and pros. The simpler IBKR Lite platform is aimed at less-active investors, but all users older than 21 must meet a $20,000 liquid net worth requirement for a cash account.

What's in this guide?

1. KYMR shares summary
2. Compare share dealing platforms
3. Is KYMR stock a buy or sell?
4. Stock performance over time
5. Can I short KYMR shares?
6. Kymera Therapeutics's financials
7. Does Kymera Therapeutics pay a dividend?
8. Other common questions

Kymera Therapeutics share price

Use our graph to track the performance of KYMR stocks over time.

Kymera Therapeutics shares at a glance

• Key figures

Information last updated 2021-02-23.

52-week range	USD$25.43 - USD$91.92
50-day moving average	USD$69.6935
200-day moving average	USD$50.3683
Wall St. target price	USD$77.8
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Kymera Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Moomoo		$0 for US stocks	Stocks, Options, ETFs	$0		N/A	Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kymera Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Kymera Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Kymera Therapeutics shares

There are currently 1.2 million Kymera Therapeutics shares held short by investors – that's known as Kymera Therapeutics's "short interest". This figure is 8% up from 1.1 million last month.

There are a few different ways that this level of interest in shorting Kymera Therapeutics shares can be evaluated.

Kymera Therapeutics's "short interest ratio" (SIR)

Kymera Therapeutics's "short interest ratio" (SIR) is the quantity of Kymera Therapeutics shares currently shorted divided by the average quantity of Kymera Therapeutics shares traded daily (recently around 154135.10362694). Kymera Therapeutics's SIR currently stands at 7.72. In other words for every 100,000 Kymera Therapeutics shares traded daily on the market, roughly 7720 shares are currently held short.

However Kymera Therapeutics's short interest can also be evaluated against the total number of Kymera Therapeutics shares, or, against the total number of tradable Kymera Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kymera Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Kymera Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.0367% of the tradable shares (for every 100,000 tradable Kymera Therapeutics shares, roughly 37 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Kymera Therapeutics.

Find out more about how you can short Kymera Therapeutics stock.

Kymera Therapeutics overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.

Frequently asked questions

• What percentage of Kymera Therapeutics is owned by insiders or institutions?

  Currently 11.999% of Kymera Therapeutics shares are held by insiders and 39.555% by institutions.

• How many people work for Kymera Therapeutics?

  Latest data suggests 64 work at Kymera Therapeutics.

• When does the fiscal year end for Kymera Therapeutics?

  Kymera Therapeutics's fiscal year ends in December.

• Where is Kymera Therapeutics based?

  Kymera Therapeutics's address is: 200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472

• What is Kymera Therapeutics's ISIN number?

  Kymera Therapeutics's international securities identification number is: US5015751044